Loading…
Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon‐like peptide‐1 (GLP‐1), a gut incretin hormone, has become a well‐established treatment for T2DM and is likely to be involved in treating cognitive impairment....
Saved in:
Published in: | The European journal of neuroscience 2021-11, Vol.54 (10), p.7749-7769 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon‐like peptide‐1 (GLP‐1), a gut incretin hormone, has become a well‐established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP‐1‐based therapeutics in AD. |
---|---|
ISSN: | 0953-816X 1460-9568 |
DOI: | 10.1111/ejn.15502 |